<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9FE0E616-6A75-4DCC-BA07-3ADF018A9669"><gtr:id>9FE0E616-6A75-4DCC-BA07-3ADF018A9669</gtr:id><gtr:name>National Cancer Research Institute</gtr:name><gtr:address><gtr:line1>National Cancer Research Institute</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78444E5F-3140-4FEC-B398-D62B796742E8"><gtr:id>78444E5F-3140-4FEC-B398-D62B796742E8</gtr:id><gtr:name>CTRad</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/70D9483D-0639-4D53-A44B-080D6B4237E1"><gtr:id>70D9483D-0639-4D53-A44B-080D6B4237E1</gtr:id><gtr:name>BTG</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:department>Brighton and Sussex Medical School</gtr:department><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9FE0E616-6A75-4DCC-BA07-3ADF018A9669"><gtr:id>9FE0E616-6A75-4DCC-BA07-3ADF018A9669</gtr:id><gtr:name>National Cancer Research Institute</gtr:name><gtr:address><gtr:line1>National Cancer Research Institute</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78444E5F-3140-4FEC-B398-D62B796742E8"><gtr:id>78444E5F-3140-4FEC-B398-D62B796742E8</gtr:id><gtr:name>CTRad</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/70D9483D-0639-4D53-A44B-080D6B4237E1"><gtr:id>70D9483D-0639-4D53-A44B-080D6B4237E1</gtr:id><gtr:name>BTG</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B668F5DB-0327-4612-BB24-3A74EB1B4CC9"><gtr:id>B668F5DB-0327-4612-BB24-3A74EB1B4CC9</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:surname>Chalmers</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G108%2F589"><gtr:id>0EE22C55-95EB-48E7-928F-BE93194B80E5</gtr:id><gtr:title>Enhancement of the therapeutic effects of fractionated and low dose rate radiotherapy by inhibition of PARP-1.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G108/589</gtr:grantReference><gtr:abstractText>Successful anti-cancer therapies exploit the differences that exist between malignant and healthy cells. However, many current treatments are limited by the damage they inflict upon the normal tissues of the body. In the case of the malignant brain tumour known as glioblastoma multiforme (GBM), the tumour cells are rapidly dividing whereas the surrounding normal brain cells are non-dividing. We have found that blocking the activity of a protein known as PARP-1 makes cells more sensitive to radiotherapy treatment, but only if they are actively dividing. Combining radiotherapy treatment with a drug that inhibited PARP-1 activity would increase the ability of the radiation to kill the rapidly dividing cancer cells without causing additional damage to surrounding healthy cells, and may therefore increase cure rates. The aim of our project is to verify that the PARP inhibitors increase the sensitivity of tumour cells derived from GBM specimens without affecting normal brain cells, and to determine the radiotherapy schedule that gives the best results. The project will also investigate the interactions that take place between PARP-1 and other molecules involved in the response to radiotherapy, with a view to identifying combinations of drug treatments that will maximise the anti-cancer effects of radiotherapy.</gtr:abstractText><gtr:technicalSummary>Aim: To enhance the effectiveness of conventional radiotherapy regimes by inhibiting the function of the nuclear protein poly(ADP-ribose) polymerase-1 (PARP-1).
Background: PARP-1 is rapidly activated by single and double strand breaks in DNA, and contributes to resolution of these lesions by modulating multiple DNA repair pathways. The observation that PARP-1 inhibitors sensitise actively dividing but not growth-arrested human tumour cells to ionising radiation suggests that PARP-1 inhibition might enhance the therapeutic ratio of conventional radiotherapy regimes. Pronounced sensitisation of certain cell lines to very low doses of radiation, and evidence that PARP-1 inhibition reduces the rate of DNA strand break repair, indicates that PARP-1 inhibition and continuous low dose rate radiotherapy might a particularly effective combination. 
Objectives:
1. To ascertain the extent to which PARP-1 inhibition enhances sensitivity of human tumour cells to fractionated and continuous low dose rate radiation, and to identify the common features of those cell lines in which radiosensitisation is most marked.
2. To elucidate the mechanisms underlying the radiosensitising effects of PARP-1 inhibition.
Methods:
1. The effect of inhibition of PARP-1 on radiosensitivity of a variety of human tumour cell lines will be measured using an established clonogenic survival assay. Highly potent and specific PARP-1 inhibitors will be used in collaboration with KuDOS Pharmaceuticals. Cells will be exposed to three radiation regimes: a range of single acute doses (0.05-5 Gy); a series of daily 2 Gy fractions; and continuous low dose rate radiation (in collaboration with the Gray Cancer Institute). Cell line characteristics that correlate with the magnitude of the radiosensitising effect of PARP-1 inhibition will be identified.
2. The interactions that determine radiation sensitivity will be investigated by measuring the effect of PARP-1 inhibition on clonogenic survival in cell lines lacking specific DNA repair proteins. Cells deficient in ATM, XRCC1, DNA-PKcs and BRCA1 are available at the host institute; PARP-1 and PARP-2 knockout cell lines will be provided by Gilbert de Murcia. Relevant associations will be characterised by biochemical analysis of protein-protein interactions in vitro. Comet assays and assessment of H2AX foci will enable quantitative analysis of the effect of PARP-1 status on resolution of DNA single and double strand breaks. The relative contributions of PARP-1 and PARP-2 to radiation sensitivity will be elucidated by measuring survival, DNA repair and protein interactions in PARP-1 and PARP-2 knockout cell lines.</gtr:technicalSummary><gtr:fund><gtr:end>2008-11-03</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-10-04</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>673137</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>CTRad</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK glioblastoma radiotherapy-drug combinations consortium</gtr:description><gtr:id>79B1DF99-16FD-4673-AD19-6CBDD496FA06</gtr:id><gtr:impact>Workshop taking place in Glasgow on 16-17 March 2017</gtr:impact><gtr:outcomeId>58c042b603f895.86049021-1</gtr:outcomeId><gtr:partnerContribution>CTRad supporting workshop expenses and travel for invited speakers.
NCRI Brain Tumour CSG supporting workshop administration.
Clinical Trials Unit Glasgow supporting workshop administration and future development of the clinical trial.</gtr:partnerContribution><gtr:piContribution>Based on my previous scientific and clinical research in this field I initiated and am organising and hosting a workshop aimed at developing a multi-centre, multi-arm, multi-stage clinical trial of radiotherapy in combination with various DNA repair inhibitors in the treatment of glioblastoma. The consortium will include clinicians, biological and imaging scientists, pharmaceutical companies, statisticians and consumer representatives.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NCRI Brain Tumour CSG</gtr:department><gtr:description>UK glioblastoma radiotherapy-drug combinations consortium</gtr:description><gtr:id>624C8512-C7C3-4B49-A4A2-4F3A6238DBDD</gtr:id><gtr:impact>Workshop taking place in Glasgow on 16-17 March 2017</gtr:impact><gtr:outcomeId>58c042b603f895.86049021-2</gtr:outcomeId><gtr:partnerContribution>CTRad supporting workshop expenses and travel for invited speakers.
NCRI Brain Tumour CSG supporting workshop administration.
Clinical Trials Unit Glasgow supporting workshop administration and future development of the clinical trial.</gtr:partnerContribution><gtr:piContribution>Based on my previous scientific and clinical research in this field I initiated and am organising and hosting a workshop aimed at developing a multi-centre, multi-arm, multi-stage clinical trial of radiotherapy in combination with various DNA repair inhibitors in the treatment of glioblastoma. The consortium will include clinicians, biological and imaging scientists, pharmaceutical companies, statisticians and consumer representatives.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>BTG</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Biocompatibles</gtr:department><gtr:description>Local therapy for glioblastoma multiforme</gtr:description><gtr:id>A3D32689-FE04-4432-A83C-011DB7EB9786</gtr:id><gtr:impact>Clinical trial protocol developed - not funded.</gtr:impact><gtr:outcomeId>A7986B4CA87-1</gtr:outcomeId><gtr:partnerContribution>Provided reagents and intellectual discussion.</gtr:partnerContribution><gtr:piContribution>Conducted experiments, intellectual discussion.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Cancer Institute</gtr:department><gtr:description>Radiation and temozolomide interactions</gtr:description><gtr:id>83B0D48D-D8DA-419A-A366-1F804B4AFD56</gtr:id><gtr:impact>Publication: Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent. Chalmers AJ, Ruff EM, Martindale C, Lovegrove N, Short SC. Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1511-9.</gtr:impact><gtr:outcomeId>0C0037BA96C-1</gtr:outcomeId><gtr:partnerContribution>Generated additional data, co-author on paper.</gtr:partnerContribution><gtr:piContribution>Generated data, co-authors on publication.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Clinical Trials Unit (CTU) Glasgow</gtr:department><gtr:description>UK glioblastoma radiotherapy-drug combinations consortium</gtr:description><gtr:id>B6EC59BF-8E2F-441A-830B-A12B524DD4B9</gtr:id><gtr:impact>Workshop taking place in Glasgow on 16-17 March 2017</gtr:impact><gtr:outcomeId>58c042b603f895.86049021-3</gtr:outcomeId><gtr:partnerContribution>CTRad supporting workshop expenses and travel for invited speakers.
NCRI Brain Tumour CSG supporting workshop administration.
Clinical Trials Unit Glasgow supporting workshop administration and future development of the clinical trial.</gtr:partnerContribution><gtr:piContribution>Based on my previous scientific and clinical research in this field I initiated and am organising and hosting a workshop aimed at developing a multi-centre, multi-arm, multi-stage clinical trial of radiotherapy in combination with various DNA repair inhibitors in the treatment of glioblastoma. The consortium will include clinicians, biological and imaging scientists, pharmaceutical companies, statisticians and consumer representatives.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Brain Tumour Support Group</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2194D48C-A451-4C4C-8098-3F1AD7D67F31</gtr:id><gtr:impact>Informal presentation on my research and on clinical trials for patients with brain tumours.

None.</gtr:impact><gtr:outcomeId>600F506CC54</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Senior Clinical Fellowship</gtr:description><gtr:end>2014-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>AFC07354-B273-4ECB-AE91-B4FF3A6AB40F</gtr:id><gtr:outcomeId>52C0B07A2A70</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ICR MSc Oncology Module Leader</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7CAEDC2D-F020-474E-B3FE-5955DD2C3A36</gtr:id><gtr:impact>Increase in academic clinical oncology personnel in the UK. Increase in radiotherapy clinical trials.</gtr:impact><gtr:outcomeId>iHJtUC6EJGf</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>15C56078-660A-49FF-9E1B-43666151E9A7</gtr:id><gtr:title>A general framework for quantifying the effects of DNA repair inhibitors on radiation sensitivity as a function of dose.</gtr:title><gtr:parentPublicationTitle>Theoretical biology &amp; medical modelling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03c1327946d51b2f20b9df1ab44754ff"><gtr:id>03c1327946d51b2f20b9df1ab44754ff</gtr:id><gtr:otherNames>Chalmers AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1742-4682</gtr:issn><gtr:outcomeId>C0CC989C1A6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15A2D034-4B29-4B3B-9A10-419999640C68</gtr:id><gtr:title>Radioresistant glioma stem cells--therapeutic obstacle or promising target?</gtr:title><gtr:parentPublicationTitle>DNA repair</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03c1327946d51b2f20b9df1ab44754ff"><gtr:id>03c1327946d51b2f20b9df1ab44754ff</gtr:id><gtr:otherNames>Chalmers AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1568-7856</gtr:issn><gtr:outcomeId>31C21DE88BA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC5529AE-A662-44FF-A77A-4BF7FE99EBCF</gtr:id><gtr:title>Patients receiving standard-dose temozolomide therapy are at risk of Pneumocystis carinii pneumonia.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b67f3d3cd97f193d97955eddab7eda1"><gtr:id>1b67f3d3cd97f193d97955eddab7eda1</gtr:id><gtr:otherNames>Yu SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>16CC4026429</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D392A6F-6028-48A5-BDD1-6E82436A081F</gtr:id><gtr:title>Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03c1327946d51b2f20b9df1ab44754ff"><gtr:id>03c1327946d51b2f20b9df1ab44754ff</gtr:id><gtr:otherNames>Chalmers AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>17C34D97FFE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9F9BFB9-A35C-4738-88F4-43EA9FD2B278</gtr:id><gtr:title>The potential role and application of PARP inhibitors in cancer treatment.</gtr:title><gtr:parentPublicationTitle>British medical bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03c1327946d51b2f20b9df1ab44754ff"><gtr:id>03c1327946d51b2f20b9df1ab44754ff</gtr:id><gtr:otherNames>Chalmers AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1420</gtr:issn><gtr:outcomeId>6C035A35979</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B796FEBF-16CB-4DA6-8DB2-8696BA1CF7A8</gtr:id><gtr:title>Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors.</gtr:title><gtr:parentPublicationTitle>Anti-cancer agents in medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03c1327946d51b2f20b9df1ab44754ff"><gtr:id>03c1327946d51b2f20b9df1ab44754ff</gtr:id><gtr:otherNames>Chalmers AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1871-5206</gtr:issn><gtr:outcomeId>WS19iMVVLb9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FAE396A4-98F1-42E9-A3C0-8FAA6B265C43</gtr:id><gtr:title>Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bfe79c99ed83fb6ea4eaa76b8e94d418"><gtr:id>bfe79c99ed83fb6ea4eaa76b8e94d418</gtr:id><gtr:otherNames>L?ser DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>MqGbFLGoxjR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FEC4BF13-B178-44FA-9D6E-06EED9D047FC</gtr:id><gtr:title>Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets.</gtr:title><gtr:parentPublicationTitle>Seminars in radiation oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03c1327946d51b2f20b9df1ab44754ff"><gtr:id>03c1327946d51b2f20b9df1ab44754ff</gtr:id><gtr:otherNames>Chalmers AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1053-4296</gtr:issn><gtr:outcomeId>QWcWQxQssUf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFC3B297-9C2A-4093-A101-CAA4369CD887</gtr:id><gtr:title>Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a89ce910cdb4a4be994d690dc29c19b"><gtr:id>0a89ce910cdb4a4be994d690dc29c19b</gtr:id><gtr:otherNames>Dungey FA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>7FAA8A62C16</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E309DFC6-50BF-4F5E-AFC8-0BFB2F9BF59A</gtr:id><gtr:title>Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a89ce910cdb4a4be994d690dc29c19b"><gtr:id>0a89ce910cdb4a4be994d690dc29c19b</gtr:id><gtr:otherNames>Dungey FA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>BEBF1C8032B</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G108/589</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>006DC612-6329-4D37-A540-5FB2CA634720</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.5  Radiotherapy</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>